

SUPPLEMENTAL MATERIALS

SUPPLEMENTAL TABLES

Supplemental Table 1. Demographic information of patients that underwent RRP at the London Regional Cancer Program between 1994 and 1998 (*n*=99)

Variable	Value (SD)
Age (years)	62.4 (5.7)
PSA (ng/mL)	9.7 (5.2)
Follow up (years)	12.1 (1.6)
Clinical Stage	# patients (% of total)
T1	36 (36.4%)
T2	55 (55.5%)
T3	2 (2.0%)
Unknown	6 (6.1%)

Supplemental Table 2. Pathological and clinical outcomes of patients that underwent RRP at the London Regional Cancer Program between 1994 and 1998 (*n*=99)

Variable	# patients (% of total)
Pathological stage	
pT2	60 (60.6%)
pT3	35 (35.4%)
pT4	4 (4%)
Gleason	
≤6	26 (26.2%)
7	38 (38.3%)
≥8	27 (27.3%)
Unknown	8 (8.0%)
Margins	
Negative	76 (77.6%)
Positive	23 (23.2%)
Seminal vesicles	
Negative	87 (87.9%)
Positive	12 (12.1%)
Positive Nodes	0
Biochemical failure	35 (35.4%)
Hormone resistance	1 (1%)
Bone metastasis	2 (2.1%)
Solid organ metastasis	2 (2.1%)

Supplemental Table 3. Demographic information of patients that developed metastasis during follow up at the London Regional Cancer Program between 1994 and 1998 (*n*=38)

Variable	% (SD)
Age (years)	66.7 (9.76)
Clinical Stage	# patients (% of total)
T1	6 (15.7%)
T2	19 (50%)
T3	10 (26.3%)
T4	1 (2.6%)
Unknown	2 (5.2%)
Gleason	
≤7	19 (50%)
≥8	19 (50%)
Hormone resistance	31 (81.5%)
Bone metastasis	34 (89.4%)